BioNxt Solutions (CSE:BNXT; OTC:BNXTF; FSE:BXT) has announced that it will transition its research and development activities to Gen-Plus, a contract research and development organization in Munich, Germany, effective...
BioNxt Solutions (CSE:BNXT; OTC PINK:BNXTF; FSE:BXT) has announced that key milestones have been achieved in the development of BNT23001 for the treatment of multiple sclerosis (MS). BNT23001 is BioNxt’s proprietary...